Cardiac Biomarkers: Key Takeaways for Use in Heart Failure

and Acute Coronary Syndrome

Cost of Heart Failure to Society

Challenges/Opportunities for Utilizing Biomarkers in the

Management of Heart Failure

BNP and NT-proBNP for Diagnosis or Exclusion of Heart Failure

Correlations of Natriuretic Peptides With Cardiac Structure and

Function

The Differential Diagnosis of an Elevated BNP or NT-proBNP

BNP and NT-proBNP for Prognosis in Heart Failure

BNP/NT-proBNP and Stage C HF Prognosis

The Importance of Serial NP Measurements for Prognostication

in Chronic HF

IMPROVE HR: Improvements in Quality Measures at 24 Months (Patient Level Analysis)

Therapies With Effects on B-Type Natriuretic Peptide Levels

Biomarker-Guided Heart Failure Trials

Understanding Heterogeneous Results in “Guided Therapy” Trials

TIME CHF: Cost Effectiveness

Emerging Uses of Natriuretic Peptides to Guide Therapy

Emerging Biomarkers in Heart Failure

Biomarkers for Detection of Myocardial Infarction

Diagnostic Performance of Sensitive Assays for Troponin

Elevations of Cardiac Troponin Values Because of Myocardial

Injury

Elevations of Cardiac Troponin Values Because of Myocardial

Injury

Universal Classification of Myocardial Infarction

Universal Classification of Myocardial Infarction (cont)

Prognostic Use of a Sensitive Current Generation Assay for cTn

cTnl Assay Problems

Elevations of Troponins Without Overt Ischemic Heart Disease

Abbreviations

Abbreviations

Abbreviations